These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 19434652

  • 1. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Mabjeesh NJ, Amir S, Stenger A, Chen J, Matzkin H.
    Prostate; 2009 Aug 01; 69(11):1235-44. PubMed ID: 19434652
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov 01; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 4. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
    Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CY, Ellis WJ, Vessella RL.
    Urology; 1997 Aug 01; 50(2):184-8. PubMed ID: 9255285
    [Abstract] [Full Text] [Related]

  • 5. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP.
    Int J Urol; 2006 Mar 01; 13(3):238-43. PubMed ID: 16643616
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
    Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM.
    Cancer Res; 2003 Aug 01; 63(15):4662-70. PubMed ID: 12907647
    [Abstract] [Full Text] [Related]

  • 8. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 01; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 9. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T, Schalken J, Wittjes W, Ljungberg B, Lilja H.
    Prostate; 2001 Apr 01; 47(1):14-20. PubMed ID: 11304725
    [Abstract] [Full Text] [Related]

  • 10. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.
    Int J Radiat Oncol Biol Phys; 2008 Aug 01; 71(5):1302-8. PubMed ID: 18262732
    [Abstract] [Full Text] [Related]

  • 11. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y, Ito T.
    Hinyokika Kiyo; 1999 Jan 01; 45(1):25-30. PubMed ID: 10086262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.
    Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW.
    Urology; 1997 Jul 01; 50(1):100-5. PubMed ID: 9218026
    [Abstract] [Full Text] [Related]

  • 16. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):327-33. PubMed ID: 17084558
    [Abstract] [Full Text] [Related]

  • 17. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP.
    Radiother Oncol; 2008 Jul 01; 88(1):102-7. PubMed ID: 18453022
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar 01; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 20. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
    Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H.
    Prostate; 2003 Feb 15; 54(3):181-6. PubMed ID: 12518322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.